Zynrelef Unia Europejska - polski - EMA (European Medicines Agency)

zynrelef

heron therapeutics, b.v. - bupivacaine, meloxicam - ból, pooperacyjny - Środki znieczulające - zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.

Phesgo Unia Europejska - polski - EMA (European Medicines Agency)

phesgo

roche registration gmbh - pertuzumab, trastuzumab - nowotwory piersi - Środki przeciwnowotworowe - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.